Dr. Fernando Lecanda Cordero
Director of the Adhesion and Metastasis Research Group within the Solid Tumors Program.
Preferential dedication to the study of basic mechanisms of tumorogenesis and metastasis to identify new therapeutic targets in multimodal radioimmunotherapy treatments.
Postdoctoral fellow of the Government of Navarra at the Hôpital Lariboisière (U349 INSERM) in Paris.
Postdoctoral fellow of the Spanish Ministry of Education and Science at Washington University (St. Louis, Missouri, USA) (1995-1998).
Research associate at Washington University (1998-2000).
Researcher of the "Ramón y Cajal Program" (2001-2006).
Director of the Adhesion and Metastasis Laboratory (since 2004).
Researcher of the I3 Program of the MCYT (2007).
Professor of Cell Biology by the ANECA (2016).
He has participated as Principal Investigator in 24 competitive projects funded by the Ministry of Science and Technology, Ministry of Science and Innovation, Ministry of Economy and Competitiveness, Ministry of Industry, Tourism and Trade, Ministry of Health, Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III, Government of Navarra. He has also received funding from the AECC Foundation, CAN obra social La Caixa, Fundación Mutua Madrileña and other private organizations.
He has also led 8 projects funded by international agencies.
He is co-inventor of 5 patents, one of them in exploitation for the treatment of solid and hematological tumors.
AREAS OF INTEREST
- Identification of therapeutic targets of metastasis in sarcomas.
- Elucidation of mechanisms involved in tumorogenesis and bone metastasis in lung cancer.
- Search for strategies to potentiate radioimmunotherapy in some solid tumors such as breast and lung cancer.
As an educator
- He is Professor of Cell Biology by ANECA with 4 sexenios recognized.
- He has mentored 5 postdoctoral students.
- He has supervised 9 doctoral theses (3 recognized with the Extraordinary Doctorate Award), 2 of them with European Doctorate and another with International Doctorate.
- He has supervised 10 Master's theses.
- He has collaborated in 10 book chapters.
- He has supervised 8 Final Degree projects.
- He has been tutor of 6 foreign students and 17 national students.
As a researcher
He has participated as co-author in more than 80 scientific articles in international journals and in more than 100 communications to national/international congresses.
He has collaborated in the preclinical development of a new antitumor drug with the company IDP-Pharma (Barcelona).
- Preclinical development of a c-Myc blocker. It is in clinical trials to treat lung cancer and other tumors.
- Discovery of novel radioimmunotherapy combinations in triple-negative breast cancer.
- Development of refined preclinical models for immunotherapy strategies.
- 2018: Fellow of the ASBMR.
- 2009: "Research, pharmacology, and products" award. Pharmaceutical Courier.
- 2005: "Eduardo Ortiz de Landázuri" Award for Basic Research.
- 2005: Award for the best oral communication European Musculo-Skeletal Oncology Society.
- 2002: Researcher of the "Ramón y Cajal" program in the area of Molecular, Cellular, and Genetic Biology.
- 2001: Accesit "Eduardo Ortiz de Landázuri" for Basic Research.
- 2000: John Haddad Young Investigator Award, American Society for Bone and Mineral Research.
- 1998: Young Investigator Award, American Society for Bone and Mineral Research.
Latest scientific publications
- The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer May 1, 2023 | Magazine: Molecular Cancer
- Lamc2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth Jan 6, 2023 | Magazine: Clinical Cancer Research